Industry races to counter Trump MFN threat
White House demanding 85% across-the-board drug price cuts; biopharma industry hopes to avoid catastrophic policies via alternative concessions
Biopharma leaders view President Donald Trump’s push for “most favored nation” drug pricing as a serious, urgent threat. While there is broad agreement across the industry that pegging all U.S. drug prices to levels below those in peer countries is economically irrational, CEOs and lobbyists believe they must craft a politically palatable alternative or risk punitive measures that could destroy the industry.
The threat to the industry has become acute over the past two weeks as the Trump administration’s most favored nation (MFN) negotiating team has met with eight pharmaceutical companies and plans to engage with additional firms in the coming weeks, industry executives told BioCentury. None of the CEOs, executives and lobbyists BioCentury spoke with for this story were willing to be quoted or identified. ...